AZN•benzinga•
Reported Sunday, AstraZeneca's DATROWAY Shows Over 55% Response Rate In First-Line Advanced NSCLC In TROPION-Lung02 Phase 1b Trial With Immunotherapy Combinations
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on June 2, 2025 by benzinga